ATM

Clip Money Solidifies Its Position as The Largest Multi Bank Deposit Network in The United States for Businesses

Retrieved on: 
Thursday, March 14, 2024
Principal, ATM, Financial institution, Clip, Bank

This move further strengthens Clip’s position as a convenient and secure cash deposit solution for businesses, and Financial Institutions, across the US.

Key Points: 
  • This move further strengthens Clip’s position as a convenient and secure cash deposit solution for businesses, and Financial Institutions, across the US.
  • Beyond shopping mall partnerships, Clip has partnered with NCR Atleos, owner and operator of the largest independent ATM network , to incorporate business cash deposits into thousands of existing NCR Atleos cash-deposit ATMs.
  • This collaboration adds over 2,600 deposit locations to the Clip network,and holds significant potential for reaching main street businesses and previously underserved locations across 70 major metropolitan areas in the United States.
  • This network expansion, fueled by innovative collaborations, paves the way for increased accessibility, security, and efficiency for businesses nationwide.

SECU Foundation Awards Crittenton $600,000 Grant for Capital Campaign Project

Retrieved on: 
Tuesday, March 12, 2024
Mother, ATM, Partnership, Mobile app, Education, National Credit Union Administration, Trauma, NCUA, Poverty, Woman, Survivor, Housing

CHARLOTTE, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- SECU Foundation has awarded a $600,000 challenge grant to Crittenton , a Mecklenburg County non-profit dedicated to serving vulnerable women, families, and children in North Carolina.

Key Points: 
  • CHARLOTTE, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- SECU Foundation has awarded a $600,000 challenge grant to Crittenton , a Mecklenburg County non-profit dedicated to serving vulnerable women, families, and children in North Carolina.
  • The Foundation’s grant will help fund a capital campaign project to meet the current and future needs of their residential programs.
  • The Foundation’s grant and the support of so many others are ensuring Crittenton can continue their critical work for many years to come.”
    “We are grateful for our partnership with SECU Foundation and for this grant which enables Crittenton to meet our capital campaign goal, purchase our facility, and expand our parking and recreation area,” said Crittenton CEO Jada Charley.
  • Since 2004, SECU Foundation has made a collective financial commitment of over $258 million for initiatives to benefit North Carolinians statewide.

iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 12, 2024
Comparable, Adjustment, Sale, ATM, Cryptocurrency

NASHUA, N.H., March 12, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, today announced results for its fiscal fourth quarter and full year ended December 31, 2023, as compared to the corresponding period of the last fiscal year.

Key Points: 
  • Operating Expenses: Total operating expenses for the twelve months ended December 31, 2023 were $22.5 million, a 17% decrease from $27.0 million for the twelve months ended December 31, 2022.
  • Please refer to the section entitled “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss results for the twelve-month periods ended December 31, 2023 and 2022, respectively.
  • Cash and cash equivalents: Cash and cash equivalents were $21.7 million as of December 31, 2023.
  • Accordingly, iCAD believes it has sufficient cash resources to fund its current planned operations with no need to raise additional funding.

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
ODD, Retina, Stargardt disease, Research, Conference, Vitamin A, Exercise, RPD, Eye, Patient, RBP4, Tissue, ARVO, ATM, Safety, Paratriathlon, Therapy, Macular degeneration, Blood, FDA, DRAGON, Food, Pharmaceutical industry

ET

Key Points: 
  • ET
    SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its audited financial results for full-year 2023 and the unaudited and unreviewed financial results for the quarter ended December 31, 2023, and provided a business update.
  • The decrease resulted primarily from higher R&D expenses in the fourth quarter of 2022 as the DRAGON trial reached certain milestones in such quarter.
  • Belite Bio will host a webcast on Tuesday, March 12, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.
  • A replay will be available for approximately 90 days following the event at the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events .

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
MUC, Human, Biotechnology, CSPC, Drug discovery, Carcinoma, Cervical cancer, Rash, Patient, MMAE, Tumor microenvironment, Peripheral neuropathy, IND, PH1b, Insulin resistance, Investment, Investigational New Drug, Therapy, CB1, ATM, Safety, Liraglutide, CMO, FDA, PD-1, Pharmaceutical industry

We expect to dose the first patient in our US Ph1 study in March 2024.

Key Points: 
  • We expect to dose the first patient in our US Ph1 study in March 2024.
  • For CRB-601, the FDA cleared our Investigational New Drug (“IND”) application in January 2024, and we expect to dose the first patient this summer.
  • The Company presented CRB-913 pre-clinical data at Obesity Week as an oral presentation and as a late breaking poster in October 2023.
  • The Company is currently conducting IND enabling studies and expects to file an IND in the fourth quarter of 2024.

New Found Reports Positive Phase 1 Metallurgical Test Results Demonstrating 90% to 96% Gold Extraction at Queensway

Retrieved on: 
Wednesday, April 3, 2024
Mining, Minerals, Natural Resources, TSX Venture Exchange, Queensway, Lotto, Gold, Sale, NFG, Security (finance), Disclosure, MMSA, Metallurgy, National instrument, Bank statement, BWI, Annual report, Ontario Highway 115, SAG, ATM, Process, CIL, Multimedia, Engineering, Extractive metallurgy

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    Phase I metallurgical testing commenced in 2023 and focused on three mineralized zones – Keats Main, Golden Joint, and Lotto.
  • Weighted average gold extraction on all 116 Variability Composite samples, broken out by the five cross sections shown in Figures 1-6, range from 90% to 96%.
  • Gold extraction across the three zones tested in Phase I demonstrates similar metallurgical characteristics and achieved similar extractions from both gravity and CIL.
  • Metallurgical test work at Queensway has been designed and supervised by Gary Simmons (MMSA QP Number: 01013QP) as an independent consultant.

Navy Federal Credit Union Now Operates Department of Defense Overseas Military Banking Facilities

Retrieved on: 
Tuesday, April 2, 2024
Professional Services, Defense, Insurance, Military, Finance, Banking, Veterans, Active duty, Navy Federal Credit Union, ATM, Community Bank, MBF, Credit, Navy, Bank

Navy Federal Credit Union has officially started operating the Military Banking Facilities (MBF) overseas, known as "Community Bank."

Key Points: 
  • Navy Federal Credit Union has officially started operating the Military Banking Facilities (MBF) overseas, known as "Community Bank."
  • These MBFs are part of the Department of Defense (DoD) Overseas Military Banking Program.
  • MBFs overseas will now be co-branded as "Community Bank, Operated by Navy Federal Credit Union.”
    “The Overseas Military Banking Program fits our core values at Navy Federal and is consistent with our primary mission of supporting Active Duty military members and their families,” said Kara Cardona, COO of Navy Federal.
  • While Navy Federal Credit Union now operates these MBFs overseas, these institutions will remain as separate entities.

GoldATM Continues US Expansion with Installation of 11 Gold ATM Kiosks in Nevada

Retrieved on: 
Monday, April 1, 2024
Professional Services, Mining, Minerals, Finance, Natural Resources, Banking, Personal Finance, ATM, ATMIA, Silver, Gold, Multimedia, Movement, Cryptocurrency

Following the success of initial Q1 installations in Salt Lake City, GoldATM , an emerging leader in the ATM industry, today announced the installation of 11 operational Gold ATMs in Nevada, following the company’s official launch at ATMIA 2024 in February.

Key Points: 
  • Following the success of initial Q1 installations in Salt Lake City, GoldATM , an emerging leader in the ATM industry, today announced the installation of 11 operational Gold ATMs in Nevada, following the company’s official launch at ATMIA 2024 in February.
  • View the full release here: https://www.businesswire.com/news/home/20240401072123/en/
    GoldATM is making the purchase of gold more convenient and readily available for all.
  • The bills are flexible and durable, like cash, and are available through the kiosks for as little as $20.
  • Additionally, Goldbacks are classified as “Specie Legal Tender,” in a growing list of states including Nevada, making them a recognized form of alternative gold currency.

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, The Lancet, Research, Graft-versus-host disease, LD, ASH, International Society, Partnership, Central nervous system, ATRA, Epstein–Barr virus, Patient, Follicular lymphoma, CNS, Biomarker, PTLD, Cancer, Lymphoproliferative disorders, SLE, EBV, NHL, Lymphoma, Mantle cell lymphoma, Investment, ATM, Safety, Pharmacokinetics, Depreciation, File, Workforce, Cell, FDA, BLA, Lupus nephritis, CD19, Food, Autoimmune disease, Pharmaceutical industry

“We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.

Key Points: 
  • “We are expanding Atara’s proven EBV T-cell platform into allogeneic CAR T therapy for both oncology and autoimmune disease,” said Pascal Touchon, President and Chief Executive Officer of Atara.
  • “This includes strong momentum for our lead CAR T program, ATA3219, which is positioned to deliver near-term clinical data for both non-Hodgkin’s lymphoma and lupus nephritis.
  • Subjects will receive lymphodepletion (LD) treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 27, 2024
Technology, Biotechnology, FDA, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Janus, Vivo, Gene editing, Precision BioSciences, Patient, Cash, Mitochondrion, Health care, Infant, NHP, IND, Duchenne muscular dystrophy, Investment, Therapy, ATM, Lilly, Precision, Cell, Skeletal muscle, Hepatitis B, Rachel Haurwitz, Central nervous system, Novartis, Primate, RNA, DNA, Mitochondrial disease, Hepatology, CRISPR, Safety, VWAP, PMM, Food, AAV, Development, Prevail, Publishing, Gene, ASX, University, Diaphragm, OTC, Hemoglobinopathy, IMU, Economics, Administration, Sickle cell disease, PCSK9, CTA, MHRA, Reindeer, Heart, Autoimmune disease, Eli Lilly and Company, DMD

PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.

Key Points: 
  • PBGENE-HBV (Viral Elimination Program): Precision is developing PBGENE-HBV for the treatment of patients with chronic hepatitis B.
  • In November 2023, Precision presented preclinical efficacy and safety data at the 2023 American Association for the Study of Liver Diseases Annual Meeting.
  • Cash and Cash Equivalents: As of December 31, 2023, Precision had $116.7 million in cash and cash equivalents.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $7.0 million, as compared to $10.6 million for the quarter ended December 31, 2022.